Gene:
CYP24A1
cytochrome P450, family 24, subfamily A, polypeptide 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs2762939 14266C>G, 22977343G>C, 52781251G>C, 733-149C>G
G > C
Intronic
No VIP available No Clinical Annotations available VA
rs3787554 12837C>T, 22978772G>A, 52782680G>A, 641-308C>T
G > A
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  CP24; P450-CC24
PharmGKB Accession Id: PA27097

Details

Cytogenetic Location: chr20 : q13.2 - q13.2
GP mRNA Boundary: chr20 : 52769988 - 52790516
GP Gene Boundary: chr20 : 52766988 - 52800516
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. Vitamin D (calciferol) metabolism - (Reactome via Pathway Interaction Database)
  2. Vitamins - (Reactome via Pathway Interaction Database)
No related genes are available

Curated Information ?

Curated Information ?

Publications related to CYP24A1: 7

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 2013. Ramnath N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D(3) through CYP3A4 induction in vitro and in vivo: Implications for drug-induced osteomalacia. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2012. Wang Zhican, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human PXR-mediated induction of intestinal CYP3A4 attenuates 1alpha,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cells. Biochemical pharmacology. 2012. Zheng Xi Emily, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations in CYP24A1 and Idiopathic Infantile Hypercalcemia. The New England journal of medicine. 2011. Schlingmann Karl P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of the vitamin D metabolism gene CYP24A1 with coronary artery calcification. Arteriosclerosis, thrombosis, and vascular biology. 2010. Shen Haiqing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Asthma and genes encoding components of the vitamin D pathway. Respiratory research. 2009. Bossé Yohan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. The Journal of clinical investigation. 2005. Pascussi Jean Marc, et al. PubMed

LinkOuts

Entrez Gene:
1591
OMIM:
126065
UCSC Genome Browser:
NM_000782
RefSeq RNA:
NM_000782
NM_001128915
RefSeq Protein:
NP_000773
NP_001122387
ALFRED:
LO185531X
HuGE:
CYP24A1
Comparative Toxicogenomics Database:
1591
ModBase:
Q07973
HumanCyc Gene:
HS00395
HGNC:
2602

Common Searches